Ethical, Regulatory and Market related aspects of Deploying Triple Artemisinin-Based Combination Therapies for Malaria treatment in Africa: A study protocol.

Wellcome Open Research

article

Paulina Tindana¹  Freek de Haan²  Olugbenga Ayodeji Mokuolu³  Rosemonde Guissou⁴  Oladimeji Akeem Bolarinwa⁵  Jean Bosco Ouedraogo⁴  Fatoumata Tou⁶  Wouter P.C Boon²  Ellen H.M Moors²  Arjen M Dondorp⁷  Mehul Dhorda⁷  Chanaki Amaratunga⁷  Phaik Yeong Cheah⁷ 

[1] Department of Health Policy, Planning and Management, School of Public Health, College of Health Sciences, University of Ghana;Copernicus Institute of Sustainable Development, Utrecht University;Paediatrics Department, University of Ilorin;Institut de Recherche en Sciences de la Sante;Department of Epidemiology and Community Health, University of Illorin;Institut des Sciences et Techniques;Mahidol-Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University;Center for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford

关键词: Malaria;    Africa;    drug resistance;    ethics;   

DOI  :  10.12688/wellcomeopenres.16065.1

学科分类：内科医学

来源: Wellcome

【 摘 要 】

Introduction: According to the World Malaria Report 2019, Africa accounts for 94% of the global malaria deaths. While malaria prevalence and mortality have declined over the years, recent reports suggest that these gains may stand the risk of being reversed if resistance to Artemisinin Combination Therapies (ACTs) spreads from Southeast Asia to Africa. Efforts are being made to develop new treatments that will address the looming threat of ACT resistance, including the development of triple artemisinin combination therapies (TACTs). The proposed study seeks to explore the views of stakeholders on the key ethical, regulatory and market-related issues that should be considered in the potential introduction of triple artemisinin combination therapies (TACTs) in Africa.Methods: The study employed qualitative research methods involving in-depth interviews and focus group discussions (FGDs) with stakeholders, who will be directly affected by the potential deployment of triple artemisinin combination treatments, as regulators, suppliers and end-users. Participants will be purposively selected and will include national regulatory authorities, national malaria control programs, clinicians, distributors and retailers as well as community members in selected districts in Burkina Faso and Nigeria.Discussion: The proposed study is unique in being one of the first studies that seeks to understand the ethical, social, regulatory and market position issues prior to the development of a prospective antimalarial medicine.

【 授权许可】

CC BY